What's next in neurology — November 13, 2026
This issue covers four milestones between December 4, 2026 and May 1, 2027: the AES annual epilepsy meeting and three FDA reviews in rare diseases (pyruvate dehydrogenase complex deficiency, spinocerebellar ataxia, and Huntington's disease). Meeting dates are those published by the organizer; regulatory dates are FDA target action dates reported by each company, not guaranteed decisions, and they may change. When a date is not a specific day, it is labeled as estimated, with its source.
1. American Epilepsy Society Annual Meeting (AES 2026)
[Congress] [United States (Denver)] [Confirmed date: December 4–8, 2026]
What it is: The AES annual meeting, with its program now published. Among announced data: Xenon expects multiple new presentations on azetukalner (a Kv7 potassium channel opener), whose application for focal seizures it submitted to the FDA in September 2026 based on the X-TOLE (phase 2b) and X-TOLE2 (phase 3, NCT05614063) trials; FDA filing acceptance and an action date have not been announced. In the same window, the FDA target action date for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies is December 27, 2026, per Praxis Precision Medicines (covered in our October 13 issue).
What problem it solves: About one third of people with epilepsy keep having seizures despite drug treatment; currently clinicians switch or add antiseizure medications (lacosamide, cenobamate, brivaracetam, among others) or consider surgery or neuromodulation.
Critical take: Congress data are usually company analyses without peer review; the history of retigabine, another Kv7 opener that received an FDA warning in 2013 for blue discoloration of the skin, nails, mucous membranes, and sclera and that GSK discontinued in 2017 because of very limited use, calls for close attention to long-term safety; in addition, Xenon paused enrollment of new patients in its phase 3 depression studies after analyzing neuropsychiatric adverse events.
Sources
- [Meeting] AES 2026 Annual Meeting, meeting page, December 4–8, 2026. https://aesnet.org/AES-annual-meeting
- [Official release] Xenon Pharmaceuticals, November 9, 2026. https://www.sec.gov/Archives/edgar/data/0001582313/000119312526453521/xene-ex99_1.htm
- [Registry] NCT05614063, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05614063
- [Official release] Xenon Pharmaceuticals, September 17, 2026. https://finviz.com/news/393312/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program
- [Coverage] NeurologyLive, June 15, 2017. https://www.neurologylive.com/view/anticonvulsant-potiga-discontinued-june-2017
- [Official release] Praxis Precision Medicines, extension of the relutrigine review period, June 29, 2026. https://investor.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-extension-period
2. Oral sodium dichloroacetate (SL1009) in pyruvate dehydrogenase complex deficiency
[Pending regulatory decision] [United States] [FDA target action date: December 30, 2026, per Saol Therapeutics]
What it is: Oral dichloroacetate with dosing guided by a genetic test of GSTZ1 genotype. The phase 3 double-blind crossover trial SL1009-01 (NCT02616484) did not reach significance on its primary motor endpoint in the double-blind phase, and the companion study SL1009-02 compared survival of treated patients with an external natural history cohort. In August 2025, the FDA found the evidence insufficient, questioned the comparability of the external cohort and requested a new adequate trial; the letter also asked for a thorough QT study and a food-effect pharmacokinetic study. Saol reported adding the requested survival analyses to its resubmission after subsequent meetings, with no new trial; the FDA accepted the resubmission as a complete class 2 response.
What problem it solves: Pyruvate dehydrogenase complex deficiency causes lactic acidosis, encephalopathy, and early childhood death and has no FDA-approved treatment; currently care relies on measures such as the ketogenic diet and thiamine. SL1009 is investigational, and an expanded access program (NCT06931262) exists, subject to eligibility.
Critical take: Efficacy rests on secondary analyses and on an external-control comparison that, according to the FDA letter, could not be used to estimate an effect on survival, with risk of bias; peripheral neuropathy is a known adverse effect of dichloroacetate that genotype-guided dosing aims to reduce.
Sources
- [Regulator] FDA, complete response letter (CRL) for NDA 218679, August 27, 2025. https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf
- [Official release] Saol Therapeutics, July 28, 2026. https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html
- [Registry] NCT06931262, ClinicalTrials.gov (expanded access program). https://clinicaltrials.gov/study/NCT06931262
- [Coverage] NeurologyLive, August 4, 2026. https://www.neurologylive.com/view/fda-accepts-sl1009-resubmission-pdcd-sets-december-pdufa-date
3. Troriluzole (Vyglxia) in spinocerebellar ataxia: a new FDA review
[Pending regulatory decision] [United States] [Estimated date: first quarter of 2027 (FDA goal date, per Biohaven; may be extended); advisory committee beforehand, not yet scheduled]
What it is: An oral prodrug of riluzole, a glutamate modulator. On October 22, 2026, Biohaven reported that the FDA accepted the resubmission as a complete response to its November 4, 2025 action letter and plans to convene its Peripheral and Central Nervous System Advisory Committee. The main evidence is the three-year Study 206-RWE, which compares treated patients with matched untreated external controls from two natural history studies (US and Europe); the randomized, double-blind phase 3 trial (Study 206) did not reach significance on its primary endpoint (change in modified f-SARA at week 48) in the overall population.
What problem it solves: Spinocerebellar ataxias are progressive and have no approved treatment in the US; currently management is rehabilitation, fall prevention, and symptomatic care.
Critical take: In its November 4, 2025 letter, the FDA concluded that Study 206-RWE could not be considered an adequate and well-controlled investigation because of design flaws and methodological limitations that introduced bias, including potential unmeasured confounding in the comparison with external controls, and asked for data from an adequate and well-controlled study; the resubmission adds analyses, not a new randomized trial, and the advisory committee will be the most informative signal.
Sources
- [Regulator] FDA, complete response letter (CRL) for NDA 210862, November 4, 2025. https://download.open.fda.gov/crl/CRL_NDA210862_20251104.pdf
- [Official release] Biohaven, Form 8-K filed with the SEC, October 22, 2026. https://www.sec.gov/Archives/edgar/data/0001935979/000193597926000083/bhvn-20261022.htm
- [Coverage] NeurologyLive, October 22, 2026. https://www.neurologylive.com/view/fda-accepts-troriluzole-nda-resubmission-spinocerebellar-ataxia
- [Official release] Biohaven, May 23, 2022. https://www.biospace.com/biohaven-provides-update-on-phase-3-clinical-trial-evaluating-troriluzole-for-spinocerebellar-ataxia-sca
4. AMT-130 (ifezuntirgene inilparvovec), gene therapy for Huntington's disease
[Pending regulatory decision] [United States] [FDA target action date: May 1, 2027, per uniQure; advisory committee tentatively planned, not yet scheduled]
What it is: An AAV5 vector carrying a microRNA against huntingtin, given once by stereotactic neurosurgery into the striatum. On November 2, 2026, uniQure announced that the FDA accepted the application, submitted under the accelerated approval pathway, with priority review; it relies on 36-month data from the phase 1/2 study compared with a propensity score–matched external control from the Enroll-HD natural history database. The confirmatory trial, randomized 2:1 versus standard of care in about 200 patients with total functional capacity at 36 months as the endpoint, is planned to begin US screening by the end of 2026.
What problem it solves: No treatment slows Huntington's disease; currently only symptoms are treated (tetrabenazine or deutetrabenazine for chorea, antipsychotics, antidepressants), with multidisciplinary support.
Critical take: Few high-dose patients. The 36-month comparison used an external Enroll-HD control. The initial US study randomized participants to therapy or sham surgery and allowed later crossover; the European study was open-label. The procedure is invasive and irreversible, and the FDA tentatively plans to discuss it at an advisory committee before deciding.
Sources
- [Official release] uniQure, November 2, 2026. https://finviz.com/news/413042/uniqure-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-ifezuntirgene-inilparvovec-for-the-treatment-of-huntingtons-disease
- [Official release] uniQure, September 2, 2026. https://uniqure.gcs-web.com/node/12991
- [Official release] uniQure, Huntington's disease program page. https://uniqure.com/programs-pipeline/huntingtons-disease
- [Official release] uniQure, AMT-130 phase I/II trial page. https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130
- [Registry] NCT05243017, ClinicalTrials.gov (European study). https://clinicaltrials.gov/study/NCT05243017
Ready-to-paste WhatsApp text
*What's next in neurology — November 13, 2026* 1. AES epilepsy meeting, Denver: Dec 4–8, 2026 (new azetukalner data). 2. SL1009 (dichloroacetate) in pyruvate dehydrogenase deficiency: FDA target action date Dec 30, 2026, per Saol. 3. Troriluzole in spinocerebellar ataxia: FDA review goal in Q1 2027, per Biohaven (may be extended), with an advisory committee. 4. AMT-130, Huntington's gene therapy: FDA target action date May 1, 2027, per uniQure. With a critical take on each item and official sources. Full issue and audio: https://boletinesmedicos.com/en/neurology/2026-11-13-viene.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
What's next in neurology (December 2026 – May 2027), with dates from official sources (regulatory dates are FDA target action dates, per each company): • Dec 4–8, 2026: AES epilepsy meeting in Denver. • Dec 30, 2026: FDA target action date, per Saol, for dichloroacetate (SL1009) in pyruvate dehydrogenase deficiency. • Q1 2027: FDA review goal, per Biohaven, for troriluzole in spinocerebellar ataxia, based on external controls. • May 1, 2027: FDA target action date, per uniQure, for AMT-130, Huntington's gene therapy; accelerated approval pathway requested. Each item covers the problem it addresses, current practice, and a critical take. Full issue and audio: https://boletinesmedicos.com/en/neurology/2026-11-13-viene.html #Neurology #Epilepsy #Huntingtons #BoletinesMedicos
Ready-to-paste X (Twitter) post
What's next in neurology: AES epilepsy meeting (Dec 4–8, 2026) and FDA target dates for dichloroacetate, troriluzole and AMT-130 for Huntington's: https://boletinesmedicos.com/en/neurology/2026-11-13-viene.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.